Matching articles for "Targin"
Correction: Abuse-Deterrent Opioids
The Medical Letter on Drugs and Therapeutics • July 16, 2018; (Issue 1551)
In our article on abuse-deterrent opioids (Med Lett Drugs Ther 2017; 59:95), the information on Targiniq ER in Table 1 is incorrect. The drug, which is not available in the US, is a combination of oxycodone ER...
In our article on abuse-deterrent opioids (Med Lett Drugs Ther 2017; 59:95), the information on Targiniq ER in Table 1 is incorrect. The drug, which is not available in the US, is a combination of oxycodone ER and naloxone, not naltrexone, and naloxone is dispersed throughout the tablet, not sequestered. Targiniq ER will be deleted from the table in the article as it appears on our website.
Abuse-Deterrent Opioids
The Medical Letter on Drugs and Therapeutics • June 5, 2017; (Issue 1522)
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and
public health advocates. Since our last article on
this...
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and
public health advocates. Since our last article on
this subject, several new abuse-deterrent opioid
formulations have been approved by the FDA,
including an oxycodone tablet formulation (Roxybond
– Inspirion) that is the first immediate-release opioid
product FDA-approved to include claims of abuse
deterrence in its labeling. No opioid formulation
prevents consumption of a large number of intact
dosage units, the most common method of abuse.
Abuse-deterrent formulations have one or more
properties that make their intentional nontherapeutic
use more difficult, less attractive, or less rewarding.
A New Abuse-Deterrent Opioid - Xtampza ER
The Medical Letter on Drugs and Therapeutics • June 20, 2016; (Issue 1497)
The FDA has approved Xtampza ER (Collegium),
a new extended-release, abuse-deterrent capsule
formulation of oxycodone, for management of pain
severe enough to require daily, around-the-clock,
long-term...
The FDA has approved Xtampza ER (Collegium),
a new extended-release, abuse-deterrent capsule
formulation of oxycodone, for management of pain
severe enough to require daily, around-the-clock,
long-term opioid treatment and for which alternative
treatment options are inadequate.
Abuse-Deterrent Opioid Formulations
The Medical Letter on Drugs and Therapeutics • August 31, 2015; (Issue 1476)
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and public
health advocates. Three available opioid...
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and public
health advocates. Three available opioid formulations,
OxyContin (Purdue), Embeda (Pfizer), and Hysingla ER
(Purdue), now include claims of abuse deterrence in
their package inserts.